NA
SVA

Navellier & Associates’s Sinovac Biotech, Ltd SVA Stock Holding History

Navellier & Associates’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,018
Closed – – 370
2025
Q4 		$0 Sell
13,018
-550
-4% – ﹤0.01% 390
2025
Q3 		$0 Buy
13,568
+409
+3% – ﹤0.01% 384
2025
Q2 		$0 Buy
+13,159
New – ﹤0.01% 321
2025
Q1 		– Sell
-14,167
Closed – – 383
2024
Q4 		$0 Hold
14,167
– – ﹤0.01% 370
2024
Q3 		$0 Hold
14,167
– – ﹤0.01% 368
2024
Q2 		$0 Sell
14,167
-121
-0.8% – ﹤0.01% 381
2024
Q1 		$0 Buy
14,288
+647
+5% – ﹤0.01% 375
2023
Q4 		$0 Sell
13,641
-1,008
-7% – ﹤0.01% 365
2023
Q3 		$0 Hold
14,649
– – ﹤0.01% 352
2023
Q2 		$0 Sell
14,649
-407
-3% – ﹤0.01% 314
2023
Q1 		$0 Hold
15,056
– – ﹤0.01% 309
2022
Q4 		$0 Buy
15,056
+189
+1% – ﹤0.01% 297
2022
Q3 		$0 Sell
14,867
-961
-6% – ﹤0.01% 313
2022
Q2 		$0 Hold
15,828
– – ﹤0.01% 340
2022
Q1 		$0 Sell
15,828
-6,350
-29% – ﹤0.01% 367
2021
Q4 		$0 Hold
22,178
– – ﹤0.01% 362
2021
Q3 		$0 Sell
22,178
-70
-0.3% – ﹤0.01% 347
2021
Q2 		$0 Hold
22,248
– – ﹤0.01% 354
2021
Q1 		$0 Hold
22,248
– – ﹤0.01% 330
2020
Q4 		$0 Sell
22,248
-538
-2% – ﹤0.01% 306
2020
Q3 		$0 Sell
22,786
-601
-3% – ﹤0.01% 272
2020
Q2 		$0 Sell
23,387
-754
-3% – ﹤0.01% 289
2020
Q1 		$0 Sell
24,141
-681
-3% – ﹤0.01% 307
2019
Q4 		$161K Sell
24,822
-2,368
-9% -$15.4K 0.03% 278
2019
Q3 		$0 Hold
27,190
– – ﹤0.01% 308
2019
Q2 		$0 Hold
27,190
– – ﹤0.01% 300
2019
Q1 		$0 Sell
27,190
-1,763
-6% -$11.6K ﹤0.01% 285
2018
Q4 		$201K Sell
28,953
-1,807
-6% -$13.2K 0.03% 210
2018
Q3 		$234K Sell
30,760
-1,105
-3% -$7.97K 0.03% 257
2018
Q2 		$238K Buy
+31,865
New +$251K 0.03% 264
2014
Q3 		– Sell
-24,800
Closed -$140K – 380
2014
Q2 		$140K Hold
24,800
– – 0.01% 318
2014
Q1 		$179K Buy
24,800
+14,550
+142% +$96.3K 0.01% 309
2013
Q4 		$63K Buy
+10,250
New +$61.8K ﹤0.01% 303

Other funds holding SVA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NAH
Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
HI
Horizon Investments Charlotte, North Carolina $8.92B AUM 25.62% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

Navellier & Associates's SVA Position: Q1 2026 in Review

Navellier & Associates sold out of Sinovac Biotech, Ltd (SVA) in Q1 2026, closing a stake of 13,018 shares.

Navellier & Associates first reported a position in SVA in Q4 2013 and held it in 33 quarters. The position peaked at $238K in Q2 2018. 28 funds tracked by Wall St. Rank hold SVA as of Q1 2026.

  • Navellier & Associates reported no remaining Sinovac Biotech, Ltd position as of Q1 2026 after selling out during the quarter.
  • Navellier & Associates sold 13,018 Sinovac Biotech, Ltd shares in Q1 2026.
  • Navellier & Associates first reported a position in Sinovac Biotech, Ltd in Q4 2013 and held it in 33 quarters.
  • Navellier & Associates's Sinovac Biotech, Ltd position peaked at $238K in Q2 2018.
  • 28 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q1 2026.

Based on Navellier & Associates's 13F filing for Q1 2026, filed 7 May 2026.